source
- Eli Lilly stops 340B discounts for hospitals that did not submit required claims dataEli Lilly has begun withdrawing the federally mandated 340B price discounts from a handful of hospitals that have failed to provide the comprehensive claims data the company requires. The move fol…
- FDA lifts opposition to Huntington’s disease gene therapy, clearing path for developmentThe Readout Loud podcast this week highlighted a regulatory shift for a gene therapy aimed at Huntington’s disease. The Food and Drug Administration reversed its earlier opposition, removing a key…